Related Experiment Videos
Expression of intercellular adhesion molecule-3 (ICAM-3/CD50) in malignant lymphoproliferative disorders and solid
M J Terol1, M C Cid, A López-Guillermo
1Postgraduate School of Hematology Farreras Valent, University of Barcelona, Spain.
Insights
Intercellular Adhesion Molecule 3 (ICAM-3/CD50) is expressed in most Non-Hodgkin
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Intercellular Adhesion Molecule 3 (ICAM-3/CD50) is a LFA-1 counter receptor involved in immune response initiation.
- Understanding ICAM-3/CD50 expression patterns in neoplasms is crucial for comprehending immune interactions in cancer.
Purpose of the Study:
- To investigate the expression of ICAM-3/CD50 in various human neoplasms, including Non-Hodgkin's lymphomas (NHL), Hodgkin's disease, and solid tumors.
- To correlate ICAM-3/CD50 expression with clinical and pathological characteristics of cancer patients.
Main Methods:
- Analysis of ICAM-3/CD50 expression in 101 NHL, 26 Hodgkin's disease cases, and 38 solid tumors.
- Immunohistochemical examination of tumor cells and tumor-associated endothelial cells.
Main Results:
- ICAM-3/CD50 was expressed in most NHLs, with a tendency for loss in high-grade lymphomas.
- Reed-Sternberg cells in Hodgkin's disease were negative for ICAM-3/CD50.
- ICAM-3/CD50 was observed on endothelial cells of tumor-associated neovascularization in both lymphoid and solid tumors.
Conclusions:
- Tumor-associated ICAM-3/CD50 expression is primarily found in hematological neoplasms, decreasing in aggressive lymphomas and Hodgkin's disease.
- Endothelial ICAM-3/CD50 expression in tumor vasculature suggests a role in tumor angiogenesis across different cancer types.
Abstract:
ICAM-3/CD50 is a recently described LFA-1 counter receptor that seems to play an important role in the initiation of immune responses. In this study we have examined the expression of ICAM-3/CD50 in a large series of human neoplasms including 101 Non-Hodgkin's lymphomas (NHL), 26 Hodgkin's disease, and 38 solid tumors to define the distribution patterns of this molecule in malignant neoplasms and their possible correlation with clinical and pathological characteristics of the patients. In NHL, ICAM-3/CD50 was expressed in almost all the tumors with a tendency to be lost in high grade lymphomas. Reed-Sternberg cells and their variants in Hodgkin's disease were always negative independently of the histological subtype of the disease. No expression was observed in tumor epithelial cells of the 38 solid tumors examined. Strong endothelial cell staining was observed in 31% of the NHL and 31% of Hodgkin's disease. ICAM-3 expression in these cases was restricted to small tumor vessels. ICAM-3 expression in endothelial cells of NHL was significantly more frequent in high grade (40%) than in low grade lymphomas (14%) (p = 0.012). In addition, tumor vessels were also positive in 29% of solid tumors independently of the histological type. No correlation was observed between ICAM-3 expression in tumor or endothelial cells and other clinical and pathological characteristics of the patients. These findings indicate that ICAM-3 expression in human tumors is restricted to hematological neoplasms with a tendency to be lost in high grade lymphomas and Hodgkin's disease. ICAM-3 is also expressed by endothelial cells from tumor-associated neovascularization in both lymphoid and solid tumors.